We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Malaria Tests Assessed After Artemisinin Therapy

By LabMedica International staff writers
Posted on 21 Oct 2013
Plasmodium falciparum-specific rapid diagnostic tests (RDTs) have been used to detect recurrent infections after artemisinin-based combination therapy (ACT).

High specificity of RDTs to distinguish an active P. More...
falciparum infection from residual antigens from a previous infection is crucial in endemic areas where residents are repeatedly exposed to malaria.

Scientists at Karolinska Institute (Stockholm, Sweden) studied 53 Tanzanian children less than five years of age with uncomplicated P. falciparum malaria infections. The children were followed up on nine occasions after initiation of artemether-lumefantrine treatment. At each visit capillary blood samples was collected for the histidine-rich protein 2 (HRP2 and lactate dehydrogenase (LDH)-based RDTs, Giemsa and acridine orange-stained blood smears for microscopy and real-time polymerase chain reaction (PCR).

The two RDTs used were the ParaHITf (Span Diagnostics Ltd.; Surat, India) that detects P. falciparum-specific HRP2 antigen and the CareStart Malaria assay (AccessBio; Somerset, NJ, USA) that detects P. falciparum-specific LDH antigen and were performed and interpreted on site. PCR genotyping was performed to distinguish reinfections from recrudescence. Assessment of clearance times and detection of recurrent P. falciparum infections were done for all diagnostic methods.

The median clearance times were 28 (range 7 to greater than 42) and 7 (2 to 14) days for HRP2 and LDH-based RDTs, 2 (1 to 7) and 2 (1 to 14) days for Giemsa and acridine orange-stained blood smear and 2 (1 to 28) days for real-time PCR. RDT specificity against Giemsa-stained blood smear microscopy was 21% for HRP2 on day 14, reaching 87% on day 42, and equal to or greater than 96% from day 14 to 42 for LDH. There was no significant correlation between parasite density at enrolment and duration of HRP2 positivity. Recurrent malaria infections occurred in 10 children and the HRP2 did not detect eight recurrent infections and LDH-based RDTs did not detect two.

The authors concluded that the LDH-based RDT was superior to HRP2-based for monitoring of treatment outcome and detection of recurrent infections after ACT in this moderately high transmission setting. The results may have implications for the choice of RDT devices in similar transmission settings for improved malaria case management. The study was published on October 1, 2013, in the Malaria Journal.

Related Links:
Karolinska Institute
Span Diagnostics Ltd.
Access Bio Inc.



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.